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Background: Serum concentration of citrulline is a useful biomarker in human intestinal disease
and indicates globally reduced enterocyte mass and absorptive function in various disease states.
Objectives: To determine whether serum citrulline concentration is a biomarker in chronic enterop-
athy (CE) in dogs, to provide useful information regarding optimal treatment or to predict outcome.
Animals: Seventy-four dogs with CE and 83 breed- and age-matched hospital controls with no
clinical signs of intestinal disease.
Methods: Retrospective study. Outcome was determined and dogs were categorized by response
to treatment as having food-responsive enteropathy (FRE), antibiotic-responsive diarrhea (ARD), or
idiopathic inflammatory bowel disease (IBD). Disease severity was quantified by the CIBDAI scor-
ing index.
Results: Serum citrulline concentration did not differ between dogs with CE (median, 8.4 mg/mL,
5th-95th percentile 2.0-19.6) and controls (median, 8.1 mg/mL, 5th-95th percentile 2.2-19.7,
P5 .91). Serum citrulline concentration was similar between dogs with FRE (median, 9.1 mg/mL,
5th-95th percentile 2.0-18.9), ARD (median, 13.0 mg/mL, 5th-95th percentile 1.6-19.2), IBD
(median, 8.4 mg/mL, 5th-95th percentile 2.1-21.0; P5 .91). Serum citrulline did not correlate to
CIBDAI or to serum albumin concentration.
Conclusions and Clinical Importance: In our study, serum citrulline concentration was not associ-
ated with efficacy of treatment or outcome in dogs with CE.
K E YWORD S
biomarker, diarrhea, IBD
1 | INTRODUCTION
Chronic enteropathy (CE) is a common condition in dogs.1 Causes of
CE can include adverse reaction to food, apparent antibiotic responsive
diarrhea (ARD) and putative idiopathic inflammatory bowel disease
(IBD), with these disorders best diagnosed retrospectively, by exclusion
of other causes and response to treatment.1,2 As histopathological
diagnosis does not reliably distinguish different causes of CE, determin-
ing the best treatment is currently undertaken on a trial-and-error
basis.1,3 Further, outcomes for individuals vary widely and are difficult
to predict, with some dogs responding to one treatment or another,
and others responding poorly.2 As a result, there is a need for novel
tests that predict the best treatment and help to determine the likely
outcome. Unfortunately, despite recent investigations into potential
Abbreviations: ARD, antibiotic-responsive diarrhea; CCECAI, canine chronic
enteropathy clinical activity index; CE, chronic enteropathy; CIBDAI, canine
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new tests,4–10 serum biomarkers that are specific to CE in dogs have
not yet been identified.
Citrulline, a nondietary amino acid involved in intermediary metab-
olism, is produced almost exclusively by the enterocytes of the small
intestinal mucosa, and is a potential biomarker in intestinal disease. Cir-
culating citrulline is dependent on de novo synthesis, as it is not found
in food (except for watermelons). Therefore, decreased serum or
plasma citrulline concentration corresponds to a reduction in function-
ing enterocyte mass.11 In human medicine, citrulline is considered to be
a reliable biomarker of remnant small intestinal enterocyte mass and
absorptive capacity, independent of intestinal inflammation.12 It is used
to determine, quantitatively, intestinal epithelial integrity at the entero-
cyte level and is not greatly influenced by nutritional status or systemic
inflammatory status.11 Decreased plasma citrulline concentration corre-
lates with reduced enterocyte mass in short bowel syndrome,13–15 vil-
lous atrophy states,16 and during follow-up of patients after small
bowel transplantation.17 Various cut-offs are employed in humans to
quantify the degree of intestinal failure and are useful in predicting
prognosis where there is intestinal compromise.18,19
To date, there have been few studies of citrulline in chronic intesti-
nal diseases of dogs.20,21 Therefore, the aims of our study were to
determine the value of citrulline as a biomarker in canine CE. The
hypothesis was that serum citrulline concentration in dogs with CE will
differ between dogs that respond to dietary management (adverse food
reaction), those that have ARD, and those that have idiopathic IBD.
2 | MATERIALS AND METHODS
2.1 | Dogs
This was a retrospective study involving client-owned dogs referred to
the Small Animal Teaching Hospital (SATH), University of Liverpool,
UK. Computer records were searched to identify dogs diagnosed with
CE between January 2012 and July 2015. The study was approved by
the University of Liverpool, Institute of Veterinary Science Research
Ethics Committee (reference no. VREC160).
2.2 | Eligibility criteria
Dogs were eligible for the study if they had clinical signs consistent
with CE, including vomiting, diarrhea, or weight loss, for a duration of
at least 3 weeks; no identified systemic or nonintestinal causes of the
clinical signs, such as exocrine pancreatic insufficiency, pancreatitis, or
hypoadrenocorticism; and normal serum or plasma creatinine concen-
tration (as advanced kidney disease might falsely increase serum citrul-
line by reduced renal clearance). Further, sufficient surplus serum had
to be available for use in the study, after diagnostic tests had been per-
formed. Control dogs were dogs presented to the SATH for reasons
other than gastrointestinal disease and included dogs with orthopedic
or dermatological disease, and blood donors. For each dog that was
identified with CE, computer records were used to identify 2 control
dogs of the same breed and of similar age (date of birth within 6
months of the dog with CE). Control dogs were included if they had
had a blood sample taken, had no signs of intestinal disease, and had
normal serum creatinine and albumin concentrations. Two possible
controls were identified for each case because not every dog had suffi-
cient residual stored serum for citrulline assay after diagnostic testing.
2.3 | Diagnostic investigations and therapeutic trials
Hematological and serum biochemical analyses were performed on
blood samples from all dogs with CE. Hypoadrenocorticism was
excluded in all dogs by cortisol assay and/or ACTH stimulation test.
Exocrine pancreatic insufficiency was excluded in all dogs by measure-
ment of serum trypsin-like immunoreactivity. All dogs subsequently
underwent abdominal radiography and ultrasonography. In dogs that
were clinically well and where findings of these investigations were
normal, dogs were treated with fenbendazole to exclude occult parasit-
ism (when this had not already been done by the referring veterinarian)
and then started on a therapeutic dietary exclusion trial, most com-
monly using a commercial hydrolyzed protein diet (eg, Royal Canin
Hypoallergenic, or Hill’s z/d diet), again unless a rigorous dietary exclu-
sion trial already been done by the referring veterinarian. If there was
no improvement in signs of gastrointestinal disease after the dietary
exclusion trial, a therapeutic antibiotic trial was started, using either
oxytetracycline (10–20 mg/kg q8h) or tylosin (20 mg/kg q8h). For dogs
that failed both dietary and antibiotic trials, or had protein losing enter-
opathy (PLE, serum albumin <2.3 g/dL), intestinal biopsy was per-
formed, most commonly by endoscopy (31 dogs underwent endoscopy
and biopsy, and 8 dogs underwent full thickness intestinal biopsy at
coeliotomy). In 4 cases in which owners declined intestinal biopsy, a
therapeutic trial with prednisolone was started in the same way as in
dogs that underwent biopsy. After diagnostic testing, dogs were fol-
lowed either by revisits to the clinic or, in a few cases, by telephone
contact with the owners (every 3–4 weeks, or more often if dictated
by the clinical situation). This refers to telephone contact at the time
rather than later.
Dogs with CE that showed resolution of their signs of gastrointes-
tinal disease after the therapeutic food trial were diagnosed with food
responsive enteropathy (FRE). Dogs with CE that did not improve by 2
weeks after starting the therapeutic food trial, but showed resolution
of their signs of gastrointestinal disease after the antibiotic trial, were
diagnosed with ARD. Dogs that did not improve on the food trial or
antibiotic trial and where intestinal inflammation was documented on
intestinal histopathology were diagnosed with idiopathic IBD.1 Inflam-
matory bowel disease was a presumptive diagnosis in dogs whose
owners declined biopsy but had unremarkable imaging findings and
who had failed to improve on the food trial or antibiotic trial. Dogs
with IBD were treated with an immunosuppressive dose (2 mg/kg/day)
of prednisolone, with the dose being subsequently reduced in dogs
that responded well. This empirical approach using therapeutic trials is
currently the most accurate way to determine a diagnosis in CE, and is
in keeping with accepted criteria for the diagnosis of FRE, ARD, and
IBD in dogs.1,22,23 Dogs with IBD were further subdivided into those
that responded well to immunosuppressive therapy and those that
were refractory to treatment. Finally, all study dogs were also
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separately classified as PLE or non-PLE based on serum albumin con-
centration. The CIBDAI scoring index was used to quantify the severity
of clinical signs and assess progression of disease.24
2.4 | Blood sampling and sample storage and
citrulline assays
Blood samples were collected from the jugular vein. Given possible
postprandial variation in plasma citrulline concentration,25 all dogs
were routinely fasted for at least 12 hours before blood collection. The
blood was centrifuged and the serum separated. Serum was stored at
2208C until citrulline assays were performed. All serum samples were
shipped frozen via courier at the end of the study period, to the same
laboratory (Laboratorio d’Analisi Veterinarie San Marco, Padova, Italy).
Time in storage was between 53 and 825 days. Serum citrulline was
measured by ultra-high performance liquid chromatography with tan-
dem mass spectroscopy. The method was validated for selectivity, line-
arity, precision, accuracy, recovery, and stability. Selectivity was
assessed by comparing the chromatogram of blank serum with those of
corresponding plasma samples spiked with L-citrulline. Sensitivity was
determined by analyzing samples spiked with L-citrulline. Intraday and
interday variation were assessed by analysis of five batches on differ-
ent days with coefficient of variation 6% and 7%, respectively. Limit of
detection was determined to be 0.050 ng/mL. The assay was found to
be linear over a citrulline concentration range of 0.194–198.8 ng/mL.
2.5 | Statistical analysis
Computer software was used to perform the analysis (GraphPad Prism
5.0). Continuous variables were assessed for normality using the
Shapiro-Wilk method. Where data were normally distributed, compari-
son between groups was by unpaired Student’s t-test. Where data
were not normally distributed, comparison between groups was by
Mann-Whitney U-test (for 2 groups) or the Kruskal-Wallis test (for
more than 2). Correlation between serum citrulline concentration and
CIBDAI or albumin concentration was performed by Spearman’s rank
correlation. The level of statistical significance was set at P< .05.
3 | RESULTS
3.1 | Dogs
A total of 286 dogs were seen for investigation of chronic signs of gas-
trointestinal disease during the study period, and of these, 74 met the
eligibility criteria. Of the control dogs identified, 83 dogs had sufficient
stored serum for citrulline analysis, meaning that a total of 157 dogs
were included in the study. The CE group comprised 29 females and
45 males, with a median age of 6.9 years (range, 0.3–15.3 years). In the
control group, there were 39 females and 44 males with a median age
of 6.5 years (range, 0.7–15.4 years). As expected, ages and breeds
were very similar between both groups with Border Collies, Cross
Breed dogs, Labrador Retrievers, and German Shepherd dogs being the
most numerous dogs included.
3.2 | Diagnosis based on investigations performed and
the results of therapeutic trials with food,
antibacterials, or prednisolone
Of the 74 animals with CE, 32 responded to a dietary trial and were
diagnosed with FRE, 4 failed a dietary trial but responded to antibacte-
rials and were diagnosed with ARD, and 38 failed to respond either to
diet or antibacterials and were diagnosed with idiopathic IBD, of which
34/38 had intestinal inflammation confirmed by biopsy. In the other 4
dogs, owners declined biopsy, and a presumptive diagnosis of IBD was
made. Of the 38 dogs with idiopathic IBD, 18 responded well to immu-
nosuppressive treatment, 18 responded poorly, and response was
unknown in 2.
3.3 | Comparison of citrulline concentration between
dogs with CE and controls
Serum citrulline concentration was similar between dogs with CE
(median 8.4 mg/mL, 5th-95th percentile 2.0–19.6) and controls (median
8.1 mg/mL, 5th-95th percentile 2.2–19.7; P5 .91, Figure 1).
FIGURE 1 Box plot comparing serum citrulline concentration
between 74 dogs with CE and 83 controls. P5 .91 (Mann-Whitney)
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3.4 | Comparison of citrulline concentration amongst
dogs with different categories of CE
Serum citrulline concentration was similar between dogs with FRE
(median 9.1 mg/mL, 5th-95th percentile 2.0–18.9), ARD (median 13.0
mg/mL, 5th-95th percentile 1.6–19.2), IBD (median 8.4 mg/mL, 5th-95th
percentile 2.1–21.0), and controls (median 8.1 mg/mL, 5th-95th percen-
tile 2.2–19.7; P5 .91). When, the IBD group was further divided into
those that responded well and those that responded poorly to immuno-
suppressive therapy, serum citrulline concentration was again not differ-
ent amongst groups (median 8.3 mg/mL, 5th-95th percentile 2.3–22.6
for dogs that responded well, and median 7.7 mg/mL, 5th-95th percen-
tile 1.4–16.8 for those that responded poorly, P5 .79, Figure 2).
3.5 | Comparison of citrulline concentration amongst
CE dogs with different disease severity
Serum citrulline concentration was compared between 16 dogs with
clinically unimportant CE (median 11.2 mg/mL, 5th-95th percentile 2.6–
19.2), 22 dogs with mild CE (median 9.9 mg/mL, 5th-95th percentile
2.4–20.9), 27 dogs with moderate CE (median 8.0 mg/mL, 5th-95th
percentile 1.3–20.9), and 9 dogs with severe CE (median 3.3 mg/mL,
5th-95th percentile 1.4–16.4), as determined by CIBDAI and was simi-
lar between groups (P5 .10). Further, there was no significant
correlation between CIBDAI and serum citrulline concentration
(r520.08, P5 .68). Finally, serum citrulline concentration was similar
between dogs that were alive at the end of the study period (median
8.1 mg/mL, 5th-95th percentile 1.6–20.1), and those that were eutha-
nized before the end of the study period (median 8.5 mg/mL, 5th-95th
percentile 2.1–16.3, P5 .43).
3.6 | Comparison between dogs with and without PLE
Serum citrulline concentration was compared between 31 dogs with
CE and associated PLE (median 7.1 mg/mL, 5th-95th percentile 1.3–
18.8), and 43 dogs with CE and normal serum albumin (median 10.0
mg/mL, 5th-95th percentile 2.5–20.0), and was similar between groups
(P5 .18, Figure 3). Further, serum citrulline concentration did not corre-
late with serum albumin concentration (r50.02, P5 .81).
4 | DISCUSSION
The main study conclusion was that serum citrulline concentration did
not differ between dogs with various types of CE or between dogs
with CE of different clinical severity. We had hypothesized that serum
citrulline might help to predict response to treatment, as determined by
response to sequentially performed therapeutic trials, but the fact that
citrulline concentrations did not vary amongst treatment groups would
suggest that this will not be possible. Another hypothesis was that
serum citrulline concentrations might be useful in predicting whether
dogs were likely to respond irrespective of treatment. However, serum
citrulline concentrations did not differ between dogs that responded
well to treatment and those that failed treatment or between those
that were still alive at the end of the study period and those that had
FIGURE 2 Box plot comparing serum citrulline concentration
between dogs with different types of CE. Data are shown from 74
dogs with CE (including 32 dogs with CE that responded to dietary
management, 4 dogs with CE that responded to antibiotic trials, 18
dogs with IBD that responded well to immunosuppression, and 18
dogs with IBD that were refractory to treatment) and 83 controls.
P5 .79 (Kruskal-Wallis)
FIGURE 3 Box plot comparing serum citrulline concentration
between 31 dogs with CE and associated PLE and 43 dogs with CE
and normal serum albumin. P5 .18 (Kruskal-Wallis)
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been euthanized because of CE. Moreover, there was no difference in
serum citrulline concentration between dogs with CE and concurrent
PLE and those with CE but no PLE, and no association was found
between serum citrulline concentrations and disease severity, as deter-
mined by CIBDAI. The latter finding contrasts with the results of a pre-
vious, albeit smaller, study that did find a negative correlation between
citrulline and the canine CE clinical activity index in 23 dogs with
IBD,21 and another study that showed a small but significant increase
in citrulline in 10 dogs that received probiotics as treatment for IBD, at
the same time that CIBDAI improved, suggesting that citrulline may
have been low in affected dogs before treatment started.20 The reason
for differences between the studies is not clear, but might relate to dif-
ferences in the populations studied, and diagnostic approach.
Therefore, although citrulline is a useful marker in human intestinal
diseases as mentioned above, the results of our study do not support
its use in the investigation and management of canine gastrointestinal
disease. The reasons for such a species difference are not clear. The
liver can contribute to circulating citrulline in dogs but not in
humans.26,27 However, no dogs in our study were diagnosed with liver
disease, and in another study canine parvoviral enteritis was associated
with a drastic decrease in serum citrulline, even though acute liver
damage was considered unlikely.28 This result is consistent with the
pathogenesis of canine parvoviral enteritis, in which extensive necrosis
of enterocytes is known to occur, and suggests that in principle citrul-
line can be assayed in dogs as a marker of enterocyte mass.
The disorders in human medicine that are associated with reduced
circulating citrulline involve significant loss or absence of functioning
enterocytes, such as short bowel syndrome,13–15 villous atrophy
states,16 intestinal failure associated with small bowel disruption and
transient double enterostomy,19 Crohn’s disease with extensive bowel
resection,12 and critical illness.18 Decreased circulating citrulline con-
centration might only occur when the loss of enterocytes is
severe.12,29,30 Citrulline concentration does not accurately indicate
overall absorptive function, especially when there is not a large reduc-
tion in enterocyte mass.11 If this is also true in dogs, it might explain
why decreases in circulating citrulline were not seen in the dogs with
CE in our study, in that the loss of functioning enterocyte mass might
not have been severe enough to cause a detectable decrease in serum
citrulline concentration. In humans, a citrulline generation test, in which
the rate of conversion of glutamine into citrulline measured over time,
has been suggested as a dynamic alternative to measurement of fasting
serum citrulline concentration. It remains unknown whether this should
become standard practice in human medicine29 but to our knowledge,
this test has not been assessed in client-owned dogs.
Our study has several limitations that should be considered. First,
the cases assessed were from a referral-only population. Therefore, the
findings might not be applicable to other populations, for example
those visiting primary care practices. Second, the study was retrospec-
tive so that samples were not taken for the purpose of the study, and
serum samples were stored for a variable time, until they could be ana-
lyzed in a batch. It is frequently considered that citrulline concentration
is more stable and more reliably measured in plasma than in serum and
it is unknown how this may have affected results. Serum samples were
not deproteinized before storage. There was no correlation between
time in storage and serum citrulline concentration (r50.01, data not
shown), but these results should be viewed with caution as citrulline
degradation could possibly occur with storage at 2208C, and it is also
possible that there could be liberation of citrulline from citrullinated
proteins that might be present in the sample.
A third limitation, also related to the retrospective nature of the
study, was the fact that clinical data were not recorded systematically
for the direct purpose of the study. As a result, we were often reliant
on the notes made by the attending clinician, and this might have led
to errors, for example in how response to treatment was classified.
Some of the dogs diagnosed with IBD that responded poorly to treat-
ment may have had alimentary lymphoma, given that histopathology
can be unreliable in GI disease and that a small number of dogs did not
have biopsies but were instead treated empirically. Further, since dogs
with missing data were excluded, the population studied might not
have been representative of all affected dogs. A future prospective
study could be considered to confirm these findings and to examine
changes of serum citrulline concentration over time.
Another limitation is that in humans, citrulline is considered as a
marker of the severity of intestinal damage, correlated to the severity
of the lesions and the length of gut affected, but this information was
not available for all dogs in our study. Neither CIBDAI nor serum albu-
min have been correlated with the extent of intestinal damage and the
true extent of the histopathological damage was not known for most
dogs in our study, because most dogs underwent endoscopic biopsy
and only a small part of the gut can be examined endoscopically.
5 | CONCLUSIONS
In this retrospective study, serum citrulline concentration did not differ
between dogs with CE and dogs attending the hospital for reasons
unrelated to intestinal disease. There did not appear to be any relation-
ship between serum citrulline and final diagnosis in canine CE. There-
fore, use of serum citrulline cannot currently be recommended in the
diagnostic investigation and clinical management of dogs with CE.
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